IP Library Granted Patent US 7,432,254
Granted Patent B2
US 7,432,254 · App. 10/038,112 · Granted Oct 7, 2008

Method for treating glaucoma IC

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,432,254
App. No.
10/038,112
Granted
Oct 7, 2008
Kind
B2
Abstract

Provided is a method of treating or ameliorating or preventing glaucoma, decreasing intraocular pressure or improving or amemliorting ocular accommodation in an animal, including a human comprising administering an intraocular pressure decreasing or accommodation improving amount of a compound of the formula I:

Claims (27)

1. A method of decreasing intraocular pressure in an animal in need thereof, comprising administering to the animal

an effective amount of pilocarpine; and

an effective amount of a compound of the formula I:

wherein

R 1 and R 2 are independently selected from hydrogen, acylamino, acyloxyalkyl, alkanoyl, alkanoylalkyl, alkenyl, alkoxy, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylamino, (C 1 -C 3 )alkylenedioxy, allyl, amino, ω-alkylenesulfonic acid, carbamoyl, carboxy, carboxyalkyl, cycloalkyl, dialkylamino, halo, hydroxy, (C 2 -C 6 )hydroxyalkyl, mercapto, nitro, sulfamoyl, sulfonic acid, alkylsulfonyl, alkylsulfinyl, alkylthio, trifluoromethyl, azetidin-1-yl, morpholin-4-yl, thiomorpholin-4-yl, piperidin-1-yl, 4-[C 6 or C 10 ]arylpiperidin-1-yl, 4-[C 6 or C 10 ]arylpiperazin-1-yl, or Ar, wherein Ar is C 6 or C 10 aryl or a 5- or 6-membered heteroaryl ring, wherein 6-membered heteroaryl ring contains one to three atoms of N, and the 5-membered heteroaryl ring contains from one to three atoms of N or one atom of O or S and zero to two atoms of N, each heteroaryl ring can be fused to a benzene, pyridine, pyrimidine, pyridazine, pyrazine, or (1,2,3)triazine, wherein the ring fusion is at a carbon-carbon double bond of Ar, Ar-alkyl, Ar—O, ArSO 2 —, ArSO—, ArS—, ArSO 2 NH—, ArNH, (N—Ar)(N-alkyl)N—, ArC(O)—, ArC(O)NH—, ArNH—C(O)—, or (N—Ar)(N-alkyl)N—C(O)—, or together R 1 and R 2 comprise methylenedioxy;

Z is hydrogen

Y is a group of the formula —CH(R 5 )—R 6 wherein R 5 is hydrogen;

R 6 is a group of the formula —W—R 7 , wherein R 7 is Rs, wherein W is —C(═O)— and Rs is a C 6 aryl;

Q is S;

M is absent; and

X is a pharmaceutically acceptable anion, or a pharmaceutically acceptable salt of the compound,

wherein aryl or Ar can be substituted with one or more substituents selected from the group consisting of acylamino, acyloxyalkyl, alkanoyl, alkanoylalkyl, alkenyl, alkoxy, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylamino, (C 1 -C 3 )alkylenedioxy, alkylsulfonyl, alkylsulfinyl, ω-alkylenesulfonic acid, alkylthio, allyl, amino, ArC(O)—, ArC(O)NH—, ArO—, Ar—, Ar-alkyl-, carboxy, carboxyalkyl, cycloalkyl, dialkylamino, halo, trifluoromethyl, hydroxy, (C 2 -C 6 )hydroxyalkyl, mercapto, nitro, sulfamoyl, sulfonic acid, 1-pyrrolidinyl, 4-[C 6 or C 10 ]arylpiperazin-1-yl-, 4-[C 6 or C 10 ]arylpiperidin-1-yl, azetidin-1-yl, morpholin-4-yl, thiomorpholin-4-yl, and piperidin-1-yl, wherein the decreased intraocular pressure treats glaucoma.

2. The method of claim 1 , wherein the compound of the formula I is 3-(2-phenyl-2-oxoethyl)-4,5-dimethylthiazolium chloride.

3. The method of claim 1 , wherein said compounds are administered intravenously.

4. The method of claim 1 , wherein said compounds are administered intracamerally.

5. The method of claim 1 , wherein R 1 is alkyl.

6. The method of claim 1 , wherein R 2 is alkyl.

7. The method of claim 1 , wherein R 1 and R 2 are both alkyl.

8. The method of claim 1 , wherein R 1 is methyl.

9. The method of claim 1 , wherein R 2 is methyl.

10. The method of claim 1 , wherein Rs is unsubstituted phenyl.

11. The method of claim 1 , wherein X is halogen.

12. The method of claim 1 , wherein X is chloride or bromide.

13. The method of claim 1 , wherein the compound of formula I is 3-(2-phenyl-2-oxoethyl)-4,5-dimethylthiazolium bromide.

14. A method of decreasing intraocular pressure in an animal in need thereof, comprising administering to the animal an effective amount of pilocarpine and 3-(2-phenyl-2-oxoethyl)-4,5-dimethylthiazolium chloride wherein the decreased intraocular pressure treats glaucoma.

15. The method of claim 1 , wherein the animal is a human.

16. The method of claim 14 , wherein the animal is a human.

Assignments (3)
CHANGE OF NAME Recorded Oct 5, 2007
From: ALTEON, INC.
To: SYNVISTA THERAPEUTICS, INC.
Reel/Frame 019920/0649 →
RELEASE OF SECURITY INTEREST (REEL/FRAME 018746/0676) Recorded Aug 7, 2007
From: BAKER BROS ADVISORS, LLC
To: SYNVISTA THERAPEUTICS, INC.
Reel/Frame 019658/0176 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jan 12, 2007
From: ALTEON INC., A DELAWARE CORPORATION
To: BAKER BROS ADVISORS, LLC, AS COLLATERAL AGENT FOR THE SECURED PARTIES
Reel/Frame 018746/0676 →